For adults diagnosed with chronic inflammatory demyelinating polyneuropathy, or CIDP, antibodies in the immune system attack healthy tissue, affecting the nerves in the arms and legs.
*Response to treatment was an improvement in a patient’s score based on an examination that measures arm and leg mobility.
†Dose-dependent increase in headache was observed in 2 g/kg treatment group.
*Eligible, commercially insured patients may pay as little as $0 for PANZYGA and may receive a maximum benefit of $12,500 per year or the cost of patient’s co-pay in a 12-month period (whichever is less) for claims received by the program. Terms and conditions/eligibility requirements apply. See full terms and conditions at PanzygaCoPay.com
- Patients must have commercial insurance to be eligible
- Patients are not eligible if they are enrolled in a state or federally funded insurance program